Exclusive: OpenAI has acquired Orchestra Bio

TechCrunchIndependentCenter2 hr. ago

OpenAI has acquired Orchestra Bio, a four-year-old AI biotechnology software startup, to enhance its biotech capabilities. The terms of the acquisition were not disclosed, though Orchestra Bio had previously raised approximately $20 million from investors such as Andreessen Horowitz, Atria, and 8VC. Orchestra Bio specializes in developing AI tools that assist biotech firms with various aspects of drug discovery, including financial tracking and managing clinical trial schedules. OpenAI plans to integrate Orchestra Bio's team and technology into its Rosalind AI model for life sciences research and its associated Rosalind Workbench tool, which helps researchers design experiments and analyze data. Notable clients of Rosalind include Moderna and Novo Nordisk. This acquisition reflects a broader trend where major AI laboratories are expanding their presence in key industries like pharmaceuticals.

Bias read (Center): The article discusses a corporate acquisition involving AI and biotechnology, focusing on technological development and industry trends. There is no mention of political figures, policies, or contentious issues, making the content apolitical.

AxiosIndependentCenter5 hr. ago

OpenAI has acquired Orchestra Bio, a startup focused on using AI to assist pharmaceutical companies in managing drug development processes. This move aligns with broader efforts by major AI firms like OpenAI and its competitor Anthropic to extend their influence beyond traditional domains such as coding and cybersecurity into scientific research. OpenAI plans to integrate Orchestra’s team and technology into its Rosalind platform, which provides AI tools tailored for life sciences researchers. Orchestra’s platform enables scientists to automate tasks such as monitoring studies and identifying potential project delays through AI agents. While financial details of the acquisition were not disclosed, this follows similar moves by Anthropic, which recently acquired Coefficient Bio for approximately $400 million. OpenAI has also partnered with major pharmaceutical companies like Novo Nordisk and Moderna to incorporate AI into drug development workflows.

Bias read (Center): The article presents factual information about corporate acquisitions and technological advancements within the AI sector without overtly favoring any particular political ideology. It discusses strategic business moves by private companies and highlights industry trends without taking a stance on政策

QuartzIndependentCenter9 hr. ago

Citrini Research has begun supporting life sciences stocks by utilizing Claude, an AI model, to design proteins for laboratory testing. The company created 211 proteins using this technology, and 17 of them were found to bind to scorpion toxins. However, the effectiveness of these proteins in blocking the toxins has not yet been tested. This development highlights the growing role of artificial intelligence in biotechnology research and drug discovery.

Bias read (Center): The article discusses the application of AI in protein design within the life sciences sector, which is primarily a technological and scientific topic. There is no indication of political controversy, bias, or framing that leans toward any particular ideological perspective. The content focuses on a

Quanta MagazineIndependentCenteryesterday

In October 2026, OpenAI announced a major breakthrough in mathematics with a proof of the 'quasi-Riemann hypothesis,' a weakened form of the famous Riemann hypothesis, which has remained unsolved for over 160 years. This achievement marks the most significant use of artificial intelligence in mathematical research to date. The quasi-Riemann hypothesis, while less ambitious than the original, still carries profound implications for understanding prime numbers, which are fundamental to number theory. Unlike previous expectations, the proof did not require introducing new mathematical concepts but instead revealed previously unnoticed connections among existing theories. Researchers such as Maksym Radziwiłł and Alexander Dunn have begun analyzing the proof, noting its potential to unlock many of the same insights as solving the full Riemann hypothesis.

Bias read (Center): The article discusses a scientific advancement in mathematics and does not involve political figures, policies, or ideological debates. The focus is purely on the academic and technical aspects of the quasi-Riemann hypothesis and its implications for number theory.